Daridorexant: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), NICE (England) and SMC (Scotland) recommended or restricted daridorexant, while CIPM (Spain) and TLV (Sweden) did not recommend it.
The record spans 3.8 years, opening at AWMSG (Wales) on 24 Mar 2022 and running to 21 Jan 2026.
AOTMIT (Poland) changed its position: not recommended on 8 Jan 2025, recommended by 21 Jan 2026, after a resubmission.
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 9 of 10 records date from 2023 or later.
Against its own class, daridorexant is an outlier: 50% of its decisive outcomes were positive, where molecules sharing ATC class N05C average 71%.
3 distinct indication wordings are recorded for daridorexant by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess daridorexant, on 24 Mar 2022; CIPM (Spain) did not open a file until 26 Feb 2025 — a moderate spread of 2.9 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
2 of the 8 agencies here assessed daridorexant more than once, AOTMIT (Poland) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for daridorexant.
The full ledger for daridorexant reads 4 not recommended, 3 recommended, 1 no benefit and 1 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 21 May 2025 | Indicación terapéutica autorizada: Tratamiento de pacientes adultos con insomnio caracterizado por presencia de síntomas… | not financed by the SNS · art. 92 c, d | source |
| AOTMIT (Poland) | 8 Jan 2025 | Quviviq reimbursement recommendation | not recommended | source |
| TLV (Sweden) | 12 Dec 2024 | Quviviq ingår inte i högkostnadsskyddet | rejection or exclusion | source |
| G-BA (Germany) | 15 Aug 2024 | Quviviq — benefit assessment §35a | added benefit: not proven | source |
| SMC (Scotland) | 8 Apr 2024 | Treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning. | accepted (restricted) | source |
5 further decisions for daridorexant, across 5 agencies, are not shown here. They include the most recent record on file, 21 Jan 2026 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- melatonin — same ATC class N05C — Psycholeptics
- midazolam — same ATC class N05C — Psycholeptics
- dexmedetomidine — same ATC class N05C — Psycholeptics
- remimazolam — same ATC class N05C — Psycholeptics
- zolpidem — same ATC class N05C — Psycholeptics
- apixaban — also decided by AOTMIT in 2026Q1
Coverage: 10 decisions for daridorexant from 8 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class N05C — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.